Cargando…

Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma

SIMPLE SUMMARY: Rhabdomyosarcoma (RMS) accounts for more than 50% of all soft tissue sarcomas in childhood and adolescence. Despite progress and intensified multimodality treatment, prognoses are extremely poor with an overall survival rate of approximately 20% in the advanced stage. Therefore, ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alijaj, Nagjie, Moutel, Sandrine, Gouveia, Zelia L., Gray, Maxim, Roveri, Maurizio, Dzhumashev, Dzhangar, Weber, Florian, Meier, Gianmarco, Luciani, Paola, Rössler, Jochen K., Schäfer, Beat W., Perez, Franck, Bernasconi, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696840/ https://www.ncbi.nlm.nih.gov/pubmed/33182650 http://dx.doi.org/10.3390/cancers12113313

Ejemplares similares

CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models
por: Timpanaro, Andrea, et al.
Publicado: (2023)

The proprotein convertase furin is required to maintain viability of alveolar rhabdomyosarcoma cells
por: Jaaks, Patricia, et al.
Publicado: (2016)

Surfaceome Profiling of Cell Lines and Patient-Derived Xenografts Confirm FGFR4, NCAM1, CD276, and Highlight AGRL2, JAM3, and L1CAM as Surface Targets for Rhabdomyosarcoma
por: Timpanaro, Andrea, et al.
Publicado: (2023)

Quantum Dot-Based Screening Identifies F3 Peptide and Reveals Cell Surface Nucleolin as a Therapeutic Target for Rhabdomyosarcoma
por: Dzhumashev, Dzhangar, et al.
Publicado: (2022)

Furin Targeted Drug Delivery for Treatment of Rhabdomyosarcoma in a Mouse Model
por: Hajdin, Katarina, et al.
Publicado: (2010)

Targeting Wild-Type and Mutationally Activated FGFR4 in Rhabdomyosarcoma with the Inhibitor Ponatinib (AP24534)
por: Li, Samuel Q., et al.
Publicado: (2013)

Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma
por: Tian, Meijie, et al.
Publicado: (2023)

FGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma
por: Sullivan, Peter M., et al.
Publicado: (2022)

Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma
por: Wu, Jerry T., et al.
Publicado: (2023)

The Proprotein Convertase Furin Contributes to Rhabdomyosarcoma Malignancy by Promoting Vascularization, Migration and Invasion
por: Jaaks, Patricia, et al.
Publicado: (2016)

Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma
por: Fiorito, Elisa, et al.
Publicado: (2022)

Targeted Disruption of the Intracellular Domain of Receptor FgfrL1 in Mice
por: Bluteau, Gilles, et al.
Publicado: (2014)

Targeting the Hedgehog Pathway in Rhabdomyosarcoma
por: Zarzosa, Patricia, et al.
Publicado: (2023)

Molecular mechanisms of Guadecitabine induced FGFR4 down regulation in alveolar rhabdomyosarcomas
por: Darvishi, Emad, et al.
Publicado: (2020)

Targeting hedgehog signaling reduces self-renewal in embryonal rhabdomyosarcoma
por: Satheesha, S, et al.
Publicado: (2016)

Therapeutic targeting of ATR in alveolar rhabdomyosarcoma
por: Dorado García, Heathcliff, et al.
Publicado: (2022)

Tissue-specific targeting of DNA nanodevices in a multicellular living organism
por: Chakraborty, Kasturi, et al.
Publicado: (2021)

Fenretinide Acts as Potent Radiosensitizer for Treatment of Rhabdomyosarcoma Cells
por: Brack, Eva, et al.
Publicado: (2021)

CD133 Positive Embryonal Rhabdomyosarcoma Stem-Like Cell Population Is Enriched in Rhabdospheres
por: Walter, Dagmar, et al.
Publicado: (2011)

FGF7–FGFR2 autocrine signaling increases growth and chemoresistance of fusion‐positive rhabdomyosarcomas
por: Milton, Christopher I., et al.
Publicado: (2021)

Receptor Tyrosine Kinases as Therapeutic Targets in Rhabdomyosarcoma
por: Crose, Lisa E. S., et al.
Publicado: (2011)

Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma
por: Fulda, Simone
Publicado: (2012)

RBPJ Is a Novel Target for Rhabdomyosarcoma Therapy
por: Nagao, Hiroko, et al.
Publicado: (2012)

Oncolytic Virus-Mediated RAS Targeting in Rhabdomyosarcoma
por: Phelps, Michael P., et al.
Publicado: (2018)

Isolation of NELL 1 Aptamers for Rhabdomyosarcoma Targeting
por: Duan, Chengchen, et al.
Publicado: (2022)

Biological Significance and Targeting of the FGFR Axis in Cancer
por: Chioni, Athina-Myrto, et al.
Publicado: (2021)

FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2020)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

Treatment of neuroblastoma and rhabdomyosarcoma using RGD-modified liposomal formulations of patupilone (EPO906)
por: Scherzinger-Laude, Karine, et al.
Publicado: (2013)

Epigenetics in rhabdomyosarcoma: cues to new biomarkers and targeted therapies
por: Megiorni, Francesca
Publicado: (2020)

High Frequency of Tumor Propagating Cells in Fusion-Positive Rhabdomyosarcoma
por: Generali, Melanie, et al.
Publicado: (2021)

FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer
por: Yang, Ying, et al.
Publicado: (2020)

Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations
por: Lima, Nadia Carvalho, et al.
Publicado: (2020)

Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy
por: Wang, Zechen, et al.
Publicado: (2023)

Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis
por: Zhang, Jinglin, et al.
Publicado: (2019)

Targeting the FGFR signaling pathway in cholangiocarcinoma: promise or delusion?
por: Wang, Jing, et al.
Publicado: (2020)

Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling
por: Xiao, Jin-Fen, et al.
Publicado: (2021)

FGFR1 is a potential therapeutic target in neuroblastoma
por: Cimmino, Flora, et al.
Publicado: (2022)

Current progress in cancer treatment by targeting FGFR signaling
por: Du, Sicheng, et al.
Publicado: (2023)

Cell-Based Small-Molecule Compound Screen Identifies Fenretinide as Potential Therapeutic for Translocation-Positive Rhabdomyosarcoma
por: Herrero Martín, David, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_v49ft7nut218n5o5fc34srdts6